These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 16213346)

  • 1. Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection.
    Jain A; Vekatramanan R; Yelochan B; Kashyap R; Marcos A; Fung J
    Transplant Proc; 2005 Sep; 37(7):3190-6. PubMed ID: 16213346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
    Jain AB; Eghtesad B; Venkataramanan R; Fontes PA; Kashyap R; Dvorchik I; Shakil AO; Kingery L; Fung JJ
    Liver Transpl; 2002 Nov; 8(11):1007-13. PubMed ID: 12424713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
    Kamar N; Guitard J; Ribes D; Esposito L; Rostaing L
    Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
    Burra P; Targhetta S; Pevere S; Boninsegna S; Guido M; Canova D; Brolese A; Masier A; D'Aloiso C; Germani G; Tomat S; Fagiuoli S
    Transplant Proc; 2006 May; 38(4):1127-30. PubMed ID: 16757285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
    Calanca LN; Fehr T; Jochum W; Fischer-Vetter J; Müllhaupt B; Wüthrich RP; Ambühl PM
    J Clin Virol; 2007 May; 39(1):54-8. PubMed ID: 17409018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.
    Kamar N; Ribes D; Izopet J; Rostaing L
    Transplantation; 2006 Oct; 82(7):853-6. PubMed ID: 17038897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recurrence and management of hepatitis C after liver transplantation].
    Oh KB; Lee SG; Lee YJ; Park KM; Hwang S; Kim KH; Ahn CS; Moon DB; Chu CW; Yang HS; Ha TY; Cho SH
    Taehan Kan Hakhoe Chi; 2003 Sep; 9(3):180-7. PubMed ID: 14515035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients.
    Trotter JF; Osborne JC; Heller M; Christians U
    Aliment Pharmacol Ther; 2005 Jul; 22(1):37-44. PubMed ID: 15963078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection.
    Aora S; Xu C; Teng A; Peterson J; Yeh LT; Gish R; Lau D; Rossi S; Lin CC
    J Clin Pharmacol; 2005 Mar; 45(3):275-85. PubMed ID: 15703363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function.
    Kamar N; Chatelut E; Manolis E; Lafont T; Izopet J; Rostaing L
    Am J Kidney Dis; 2004 Jan; 43(1):140-6. PubMed ID: 14712437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia.
    Grattagliano I; Russmann S; Palmieri VO; Portincasa P; Palasciano G; Lauterburg BH
    Clin Pharmacol Ther; 2005 Oct; 78(4):422-32. PubMed ID: 16198661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of pre-analytical conditions on plasma ribavirin concentrations.
    Gandia P; Trancart S; Nicot F; Barange K; Alric L; Izopet J; Séraissol P; Lavit M; Houin G
    Arzneimittelforschung; 2010; 60(10):636-9. PubMed ID: 21125815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease.
    Sbrana E; Xiao SY; Guzman H; Ye M; Travassos da Rosa AP; Tesh RB
    Am J Trop Med Hyg; 2004 Sep; 71(3):306-12. PubMed ID: 15381811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.
    Bruchfeld A; Lindahl K; Schvarcz R; Ståhle L
    Ther Drug Monit; 2002 Dec; 24(6):701-8. PubMed ID: 12451285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy.
    Chakrabarti S; Collingham KE; Fegan CD; Milligan DW
    Bone Marrow Transplant; 1999 Jun; 23(11):1209-11. PubMed ID: 10382964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of evidence for ribavirin monotherapy efficacy on liver fibrosis in hepatitis C virus positive renal transplant patients.
    Kamar N; Izopet J; Alric L; Rostaing L
    Transplantation; 2005 Jun; 79(12):1770-1; author reply 1771. PubMed ID: 15973189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.